Literature DB >> 20478411

Geriatric drug therapy: neglecting the inevitable majority.

Sven Stegemann1, Felix Ecker, Mario Maio, Peter Kraahs, Rainer Wohlfart, Joerg Breitkreutz, Andreas Zimmer, Daniel Bar-Shalom, Patrick Hettrich, Bianca Broegmann.   

Abstract

Demographic evolution will considerably increase the number of people aged 65 years and beyond in the coming decades. The elderly not only represent the most heterogeneous population, but also are a major user group for prescribed medicines, a predominance that will continue to further increase. Medicines and medication management are much more complex and challenging in the elderly and can only be addressed through a multidisciplinary approach. There is strong evidence that the elderly are able to properly manage their medication; however, their medications require different features than the standard medications used by adults. The elderly are exposed to several chronic disease conditions and their treatments, as well as experience age-related changes and limitations that need to be reflected in their medication management strategies. Geriatric drug therapy remains a multidisciplinary task. The health care industry, physicians, pharmacists, nurses and care givers provide and guide the patient's therapy according to individual needs, while the health care system and regulatory authorities build the necessary framework of support and resources.Any realistic and significant enhancement to the elderly patients' medicines and medication management needs to be addressed by all disciplines and stakeholders involved since the absence of any of the stakeholders in the overall process negatively impacts the achievable enhancement in geriatric drug therapy.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20478411     DOI: 10.1016/j.arr.2010.04.005

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  26 in total

Review 1.  Evidence-based strategies for the optimization of pharmacotherapy in older people.

Authors:  Eva Topinková; Jean Pierre Baeyens; Jean-Pierre Michel; Pierre-Olivier Lang
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

Review 2.  Pharmacotherapy of heart failure in the elderly: adverse events.

Authors:  Michael W Rich
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

3.  Challenges and opportunities in the design of age-appropriate drug products.

Authors:  S Stegemann
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

4.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 5.  Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals.

Authors:  Carsten Timpe; Sven Stegemann; Andrew Barrett; Siddharthya Mujumdar
Journal:  Br J Clin Pharmacol       Date:  2020-06-16       Impact factor: 4.335

Review 6.  Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare.

Authors:  Sean Esmonde; Divyesh Sharma; Aaron Peace
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

7.  Prevalence and factors associated with polypharmacy in older people with cancer.

Authors:  Justin P Turner; Sepehr Shakib; Nimit Singhal; Jonathon Hogan-Doran; Robert Prowse; Sally Johns; J Simon Bell
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

Review 8.  Older adults with difficulty swallowing oral medicines: a systematic review of the literature.

Authors:  Aoife Mc Gillicuddy; Abina M Crean; Laura J Sahm
Journal:  Eur J Clin Pharmacol       Date:  2015-11-16       Impact factor: 2.953

Review 9.  Intermediate care: the role of medicines management.

Authors:  Anna N Millar; Carmel M Hughes; A Peter Passmore; Cristín Ryan
Journal:  Drugs Aging       Date:  2014-01       Impact factor: 3.923

Review 10.  Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models.

Authors:  S Stegemann; J-P Baeyens; R Becker; M Maio; M Bresciani; T Shreeves; F Ecker; M Gogol
Journal:  Z Gerontol Geriatr       Date:  2014-06       Impact factor: 1.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.